Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Solid Tumors, KRAS Mutation; SOS1”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Early research (Phase 1)Looking for participantsNCT06659341
What this trial is testing

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

Who this might be right for
Advanced Solid Tumors Harboring KRAS G12C Mutation
Bayer 104
Early research (Phase 1)Ended earlyNCT04975256
What this trial is testing

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

Who this might be right for
Advanced CancerMetastatic CancerMalignant Neoplasm of Colon+2 more
Mirati Therapeutics Inc. 7
Early research (Phase 1)Active Not RecruitingNCT04111458
What this trial is testing

Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

Who this might be right for
Solid Tumors, KRAS Mutation; SOS1
Boehringer Ingelheim 71
Testing effectiveness (Phase 2)Active Not RecruitingNCT05578092
What this trial is testing

MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Who this might be right for
Solid TumorAdvanced Solid TumorNon Small Cell Lung Cancer+1 more
Mirati Therapeutics Inc. 228